Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial,Diabetes, Obesity and Metabolism

当前位置： X-MOL 学术 › Diabetes Obes. Metab. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial
Diabetes, Obesity and Metabolism ( IF 5.8 ) Pub Date : 2021-09-02 , DOI: 10.1111/dom.14537
Katsumi Iizuka _{1,

2} , Mike Baxter ₃ , Daisuke Watanabe ₄ , Daisuke Yabe _{1,

5,

6,

7}

Affiliation

To compare the benefits of iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi), with insulin glargine (iGlar) for reducing residual hyperglycaemia (defined as HbA1c ≥ 7% despite fasting plasma glucose [FPG] < 130 mg/dL) in Japanese people with type 2 diabetes (T2D) inadequately controlled on oral antidiabetic drugs.

中文翻译：

甘精胰岛素/利西拉来降低日本残留高血糖的益处：LixiLan JP-O2 试验的事后分析

比较 iGlarLixi（一种固定比例的甘精胰岛素 100 U/mL 和利西拉来组合物 (iGlarLixi) 与甘精胰岛素 (iGlar) 降低残余高血糖（定义为尽管空腹血糖 [FPG] 下 HbA1c ≥ 7%）的益处） 130 mg/dL) 在日本 2 型糖尿病 (T2D) 患者中，口服降糖药未得到充分控制。

更新日期：2021-11-08

点击分享查看原文

点击收藏

阅读更多本刊最新论文

全部期刊列表>>